CYP3A5 and NAT2 gene polymorphisms: Role in childhood acute lymphoblastic leukemia risk and treatment outcome

Molecular and Cellular Biochemistry

Volumn 364, Issue 1-2, 2012, Pages 217-223

  Silveira, Vanessa S ^a   Canalle, Renata ^b   Scrideli, Carlos Alberto ^a   Queiroz, Rosane G P ^a   Lopes, Luiz Fernando ^c   Tone, Luiz Gonzaga ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

^c A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Childhood ALL; CYP3A5; Genetic polymorphisms; NAT2; Susceptibility; Treatment outcome

Indexed keywords

CYTOCHROME P450 3A5;

ACUTE LYMPHOCYTIC LEUKEMIA; ALLELE; ARTICLE; BRAZIL; CANCER PATIENT; CANCER RISK; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; N ACETYLTRANSFERASE 2 GENE; PRESCHOOL CHILD; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD; TREATMENT OUTCOME;

ARYLAMINE N-ACETYLTRANSFERASE; BRAZIL; CYTOCHROME P-450 CYP3A; DISEASE-FREE SURVIVAL; ETHNIC GROUPS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS; TREATMENT OUTCOME;

EID: 84863916275     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-011-1220-8     Document Type: Article

References (30)

1. Greaves M (1999) Molecular genetics, natural history and the demise of childhood leukaemia. Eur J Cancer 35:1941-1953 (Pubitemid 30026216)
2. Pui CH (2000) Acute lymphoblastic leukemia in children. Curr Opin Oncol 12:3-12
3. Bolufer P, Barragan E, Collado M, Cervera J, López JA, Sanz MA (2006) Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leuk Res 30:1471-1491 (Pubitemid 44573473)
4. Canalle R, Burim RV, Tone LG, Takahashi CS (2004) Genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Environ Mol Mutagen 43:100-109 (Pubitemid 38332725)
5. Silveira VS, Canalle R, Scrideli CA, Queiroz RG, Tone LG (2010) Role of the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children. Environ Mol Mutagen 51(1):48-56
6. van Iersel ML, Verhagen H, van Bladeren PJ (1999) The role of biotransformation in dietary (anti) carcinogenesis. Mutat Res 443:259-270 (Pubitemid 29327279)
7. Brockmoller J, Cascorbi I, Henning S, Meisel C, Roots I (2000) Molecular genetics of cancer susceptibility. Pharmacology 61:212-227
8. Lewis DFV, Watson E, Lake BG (1998) Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. Mutat Res 410:245-270 (Pubitemid 28267162)
9. Amador AG, Righi PD, Radpour S, Everett ET, Weisberger E, Langer M, Eckert GJ, Christen AG, Campbell S Jr, Summerlin DJ, Reynolds N, Hartsfield JK Jr (2002) Polymorphisms of xenobiotic metabolizing genes in oropharyngeal carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93:440-445 (Pubitemid 41124666)
10. Agundez JA (2004) Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab 5(3):211-224 (Pubitemid 38735776)
11. Aydin-Sayitoglu M, Hatirnaz O, Erensoy N, Ozbek U (2006) Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias. Am J Hematol 81:162-170
12. Chen HC, Hu WX, Liu QX, Li WK, Chen FZ, Rao ZZ, Liu XF, Luo YP, Cao YF (2008) Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility. Eur J Cancer Prev 17(3):251-258
13. Meeker ND, Yang JJ, Schiffman JD (2010) Pharmacogenomics of pediatric acute lymphoblastic leukemia. Expert Opin Pharmacother 11(10):1621-1632
14. Rendic S, Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413-580 (Pubitemid 27293618)
15. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391 (Pubitemid 32268418)
16. Yamada S, Tang M, Richardson K, Halaschek-Wiener J, Chan M, Cook VJ, Fitzgerald JM, Elwood RK, Brooks-Wilson A, Marra F (2009) Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 10(9):1433-1445
17. Krajinovic M, Richer C, Sinnett H, Labuda D, Sinnett D (2000) Genetic polymorphisms of N-acetyltransferases 1 and 2 and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev 9:557-562 (Pubitemid 30396176)
18. Canalle R, Silveira VS, Scrideli CA, Queiroz RG, Lopes LF, Tone LG (2011) Impact of thymidylate synthase promoter and DNA repair gene polymorphisms on susceptibility to childhood acute lymphoblastic leukemia. Leuk Lymphoma 52(6):1118-1126
19. Cascorbi I, Brockmoller J, Mrozikiewicz PM, Bauer S, Loddenkemper R, Roots I (1996) Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res 56:3961-3966 (Pubitemid 26284745)
20. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J (2002) CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48:1668-1671
21. Sailaja K, Rao DN, Rao DR, Vishnupriya S (2010) Analysis of CYP3A5*3 and CYP3A5*6 gene polymorphisms in Indian chronic myeloid leukemia patients. Asian Pac J Cancer Prev 11(3):781-784
22. Borst L, Wallerek S, Dalhoff K, Rasmussen KK, Wesenberg F, Wehner PS, Schmiegelow K (2011) The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia. Eur J Haematol 86(6):477-483. doi:10.1111/j.1600-0609.2011. 01608.x
23. Pakakasama S, Mukda E, Sasanakul W, Kadegasem P, Udomsubpayakul U, Thithapandha A, Hongeng S (2005) Polymorphisms of drug-metabolizing enzymes and risk of childhood acute lymphoblastic leukemia. Am J Hematol 79:202-205 (Pubitemid 40967075)
24. Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, Bash RO, Behm FG, Camitta BM, Pui CH, Raimondi SC, Relling MV (2002) Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapyrelated myeloid malignancies. Pharmacogenetics 12:605-611 (Pubitemid 36005669)
25. Liu TC, Lin SF, Chen TP, Chang JG (2002) Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol Rep 9:327-329
26. Aplenc R, Glatfelter W, Han P, Rappaport E, La M, Cnaan A, Blackwood MA, Lange B, Rebbeck T (2003) CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol 122:240-244 (Pubitemid 36859609)
27. Lemos MC, Cabrita FJ, Silva HA, Vivan M, Placido F, Regateiro FJ (1999) Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis 20:1225-1229 (Pubitemid 29341442)
28. Rollinson S, Roddam P, Willett E, Roman E, Cartwright R, Jack A, Morgan GJ (2001) NAT2 acetylator genotypes confer no effect on the risk of developing adult acute leukemia: a casecontrol study. Cancer Epidemiol Biomarkers Prev 10:567-568 (Pubitemid 32701647)
29. Zanrosso CW, Hatagima A, Emerenciano M, Ramos F, Figueiredo A, Félix TM, Segal SL, Guigliani R, Muniz MT, Pombode-Oliveira MS (2006) The role of methylenetetrahydrofolate reductase in acute lymphoblastic leukemia in a Brazilian mixed population. Leuk Res 30:477-481 (Pubitemid 43254969)
30. Gra OA, Glotov AS, Kozhekbaeva Zh, Makarova OV, Nasedkina TV (2008) Genetic polymorphism in GST, NAT2, and MTRR and susceptibility to childhood acute leukemia. Mol Biol Mosk 42(2):214-225